|Bid||14.41 x 800|
|Ask||14.51 x 900|
|Day's Range||14.02 - 14.72|
|52 Week Range||8.65 - 21.64|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 5) Array Biopharma Inc (NASDAQ: ARRY ) Arrowhead Pharmaceuticals ...
Our latest Health Care Digest is taking names and targeting the latest in biotech and health care news.
The big shareholder groups in Orchard Therapeutics plc (NASDAQ:ORTX) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease theirRead More...
Person to watch Jennifer Cook The 25-year Genentech veteran — most recently in charge of clinical operations — after a year on the job is leading early cancer diagnostics company Grail toward a potential $500 million IPO. Grail is also launching a 50,000-person study to see if its technology can detect multiple cancer types earlier, particularly lung cancer. Technology to watch AI / ML From Daphne Koller’s Insitro to Alice Zhang’s Verge Genomics Inc., artificial intelligence and machine learning are moving beyond hype to real-time lab use.
Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ), a rare disease gene therapy company, recently went public, offering 14.29 million shares at $14 each. The shares were listed on the Nasdaq Oct. 31 and ended ...
Orchard Therapeutics is tackling "bubble baby" disease and other rare genetic conditions with gene therapy.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates are expected, not confirmed, at time of publication. BankFlorida (BFL) will issue 6.2 million shares between ...